Radcliffe Cardiology is proud to announce a new one-day event New Horizons in Amyloidosis (NHA), specially focused on providing an update on the diagnosis and treatment of cardiac amyloidosis and its sequelae in recognition of this rapidly developing field.
Hosted on www.radcliffecardiology.com, the event will be streamed on Wednesday 28 February 2024. This programme is designed to educate healthcare professionals on the evolving management practices in cardiac amyloidosis and is tailored to update and educate a variety of professionals including cardiologists, imaging specialists, electrophysiologists, primary care physicians, hematologists, and cardiac nurse practitioners.
This event, led by Course Director Prof Rodney Falk (Brigham and Women’s Hospital in Boston, US), will feature a distinguished group of faculty members who are renowned experts in the field of cardiac amyloidosis. The faculty will encompass a diverse range of medical specialties, facilitating a comprehensive, multidisciplinary approach.
Register now - We look forward to welcoming you to this first-time event.
*New Horizons in Amyloidosis’s programme will be submitted for accreditation to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 4 CME points, equating to 4 hours of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
Event starts in:
Share this event:
(Please note this programme is subject to change)
Welcome and Introduction
Session 1: Detect, Screen and Diagnose
- General diagnosis overview
- When to suspect cardiac amyloidosis
- Screening algorithms and decision support tools
Session 2: Detect, Screen and Diagnose
- Imaging masterclass 1
Assessing structure and function: Transthoracic echo with case example
- Imaging masterclass 2
Tissue characterisation: MRI with case example
- Imaging masterclass 3
Definitive diagnosis: Scintigraphy with case example
- Genotype and genetic testing
Session 3: Management of CA and its Sequelae
- Treatments for light chain management
- ATTR management: TTR stabilisers and silencers
- Future disease modifying therapy for ATTR
ATTR-CM: Where Are We Now and Where to Next?
- Session 1: Measuring Success in ATTR-CM: Now and in the Future
- Session 2: Is Reversal Within Reach?
- Session 3: Audience questions
This IME symposium is supported by an unrestricted educational grant from AstraZeneca.
Session 4: Management of CA and its Sequelae
- Arrhythmia management: AF, AV nodal disease, ventricular arrhythmias
- Treatment success: Clinical and patient reported outcomes
Brigham and Women's Hospital, Boston, US
Kevin AlexanderStanford University School of Medicine, Stanford, US
Marianna FontanaUniversity College London, London, UK
Julian GillmoreUniversity College London, London, UK
Isabelle LousadaAmyloidosis Research Consortium, Newton, US
Laura ObiciI.R.C.C.S. San Matteo Polyclinic, Pavia, IT
Márcia Waddington-CruzFederal University of Rio de Janeiro, Rio de Janeiro, BR
Increase the awareness of at-risk patients
Improve understanding of screening procedures
Provide guidance on the use of imaging for cardiac amyloidosis diagnosis
Improve awareness on current and emerging treatment
Provide guidance on the management of key comorbidities
Cardiac Failure Review (CFR) is an international, English language, peer-reviewed journal that publishes articles continually to CFRjournal.com and aims to assist time-pressured physicians to stay abreast of key advances and opinion in the area ofheart failure.
The journal comprises balanced and comprehensive review articles and original research written by leading authorities. The journal provides updates on a range of salient issues to support physicians in developing their knowledge and effectiveness in day-to-day clinical practice.
The journal endeavours to support the continuous medical education of specialist and general cardiologists and disseminate knowledge of the field to the wider cardiovascular community.
Partnership: CFR is the official journal of the Italian Heart Failure Association (ITAHFA).
Journal website: www.cfrjournal.com
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
- We build on the best science
- We work hands-on with our community
- We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com